Evidence map›Paper›PMID 35818068›Full record

ArticleGenome medicine2022

Metagenomic prediction of antimicrobial resistance in critically ill patients with lower respiratory tract infections.

Paula Hayakawa Serpa, Xianding Deng, Mazin Abdelghany, Emily Crawford, Katherine Malcolm, Saharai Caldera, Monica Fung, Aaron McGeever, Katrina L Kalantar, Amy Lyden and 9 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Genome medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06566898 (Monitoring of Antimicrobial Resistance Based on Metagenomics Analyses in Pneumonia Patients), which is not on this map. Cited by 64 papers.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed
16.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06566898 recruitingnot on this mapstarted 2024, after this paper: background citation

Monitoring of Antimicrobial Resistance Based on Metagenomics Analyses in Pneumonia Patients: a Genomic Epidemiology Study

TypeobservationalSponsorShanghai General Hospital, ChinaRan2024 to 2026Enrolled800ConditionsPneumonia, Next-generation Sequencing, Microbiome, Antimicrobial Resistance
3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 108 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Enrichment techniques for clinical metagenomics.Frontiers in cellular and infection microbiology · 2026
    Review
  15. Article
  16. Advances in the detection of Drug-Resistant bacteria: current trends and innovations.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Review
  17. Metagenomic next-generation sequencing: new horizons in microbiology.Frontiers in cellular and infection microbiology · 2026
    Review
  18. Review
  19. Review
  20. Article

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 1 country.

Paula Hayakawa Serpa *Division of Infectious Diseases, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Xianding Deng *Department of Laboratory Medicine, University of California, San Francisco, CA, USA.
Mazin AbdelghanyDivision of Infectious Diseases, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Emily CrawfordChan Zuckerberg Biohub, San Francisco, CA, USA.
Katherine MalcolmDivision of Pulmonary, Critical Care, Allergy and Sleep Medicine, Department of Medicine, University of California, San Francisco, CA, USA.
Saharai CalderaDivision of Infectious Diseases, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Monica FungDivision of Infectious Diseases, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Aaron McGeeverChan Zuckerberg Biohub, San Francisco, CA, USA.
Katrina L KalantarChan Zuckerberg Initiative, San Francisco, CA, USA.
Amy LydenChan Zuckerberg Biohub, San Francisco, CA, USA.
Rajani GhaleDivision of Infectious Diseases, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Thomas DeissDivision of Infectious Diseases, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Norma NeffChan Zuckerberg Biohub, San Francisco, CA, USA.
Steven A MillerDepartment of Laboratory Medicine, University of California, San Francisco, CA, USA.
Sarah B DoernbergDivision of Infectious Diseases, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Charles Y ChiuDepartment of Laboratory Medicine, University of California, San Francisco, CA, USA.
Joseph L DeRisiChan Zuckerberg Biohub, San Francisco, CA, USA.
Carolyn S CalfeeDepartment of Microbiology and Immunology, University of California, San Francisco, CA, USA.
Charles R LangelierDivision of Infectious Diseases, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA. chaz.langelier@ucsf.edu.
University of California, San Francisco · USChan Zuckerberg Initiative (United States) · USUniversity of California System · US

Funding

Precision Medicine in the Acute Respiratory Distress SyndromeR35HL140026 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CALFEE, CAROLYN · 2018 to 2024
$6.8M
Integrated Host/Microbe Metagenomics to Improve Lower Respiratory Tract Infection Diagnosis in Critically Ill ChildrenR01HL155418 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LANGELIER, CHARLES · 2021 to 2024
$1.6M
Profiling the Lung Transcriptome for Precision Diagnosis of Respiratory Infections using Host/Pathogen Metagenomic SequencingK23HL138461 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LANGELIER, CHARLES · 2018 to 2021
$718k
NHLBI NIH HHS K23 HL138461NHLBI NIH HHS R01 HL155418NHLBI NIH HHS R35 HL140026
6 · The paper itself

Abstract

backgroundAntimicrobial resistance (AMR) is rising at an alarming rate and complicating the management of infectious diseases including lower respiratory tract infections (LRTI). Metagenomic next-generation sequencing (mNGS) is a recently established method for culture-independent LRTI diagnosis, but its utility for predicting AMR has remained unclear. We aimed to assess the performance of mNGS for AMR prediction in bacterial LRTI and demonstrate proof of concept for epidemiological AMR surveillance and rapid AMR gene detection using Cas9 enrichment and nanopore sequencing.

methodsWe studied 88 patients with acute respiratory failure between 07/2013 and 9/2018, enrolled through a previous observational study of LRTI. Inclusion criteria were age ≥ 18, need for mechanical ventilation, and respiratory specimen collection within 72 h of intubation. Exclusion criteria were decline of study participation, unclear LRTI status, or no matched RNA and DNA mNGS data from a respiratory specimen. Patients with LRTI were identified by clinical adjudication. mNGS was performed on lower respiratory tract specimens. The primary outcome was mNGS performance for predicting phenotypic antimicrobial susceptibility and was assessed in patients with LRTI from culture-confirmed bacterial pathogens with clinical antimicrobial susceptibility testing (n = 27 patients, n = 32 pathogens). Secondary outcomes included the association between hospital exposure and AMR gene burden in the respiratory microbiome (n = 88 patients), and AMR gene detection using Cas9 targeted enrichment and nanopore sequencing (n = 10 patients).

resultsCompared to clinical antimicrobial susceptibility testing, the performance of respiratory mNGS for predicting AMR varied by pathogen, antimicrobial, and nucleic acid type sequenced. For gram-positive bacteria, a combination of RNA + DNA mNGS achieved a sensitivity of 70% (95% confidence interval (CI) 47-87%) and specificity of 95% (CI 85-99%). For gram-negative bacteria, sensitivity was 100% (CI 87-100%) and specificity 64% (CI 48-78%). Patients with hospital-onset LRTI had a greater AMR gene burden in their respiratory microbiome versus those with community-onset LRTI (p = 0.00030), or those without LRTI (p = 0.0024). We found that Cas9 targeted sequencing could enrich for low abundance AMR genes by > 2500-fold and enabled their rapid detection using a nanopore platform.

conclusionsmNGS has utility for the detection and surveillance of resistant bacterial LRTI pathogens.

Indexed as

Bacterial InfectionsRespiratory Tract InfectionsAnti-Bacterial AgentsCritical IllnessDrug Resistance, BacterialHigh-Throughput Nucleotide SequencingHumansMetagenomicsRNASensitivity and SpecificityAnti-Bacterial AgentsRNA

Identifiers

PMID35818068
PMCPMC9275031
OpenAlexW4285040932

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.